Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer

Michael F. Sarosdy, Paul Schellhammer, Gary Bokinsky, Paul Kahn, Roberto Chao, Lawrence Yore, Joseph Zadra, Daniel Burzon, Gerald Osher, Julia A. Bridge, Steven Anderson, Sonny L. Johansson, Michael Lieber, Mark Soloway, Kerry Flom

Research output: Contribution to journalArticle

236 Citations (Scopus)

Abstract

Purpose: The UroVysion fluorescence in situ hybridization assay (UroVysion Bladder Cancer Recurrence Kit, Vysis, Inc., Downers Grove, Illinois) is a multi-target assay that detects aneuploidy of chromosomes 3, 7 and 17, and loss of the 9p21 band in exfoliated cells in urine from patients with transitional cell carcinoma. We performed 2 multicenter trials. In 1 trial we compared the sensitivity of the FISH assay to the BTA Stat test (Bion Scientific, Redmond, Washington) and voided cytology in the detection of transitional cell carcinoma. In a separate study of healthy volunteers and patients with other (nontransitional cell carcinoma) conditions we determined the specificity of the FISH assay. Materials and Methods: A total of 176 patients with transitional cell carcinoma in the previous 9 months provided voided urine before cystoscopy. Each specimen was split, preserved and shipped to a central laboratory where all 3 tests were performed. All sites were blinded to results. Sensitivity calculations were based on central pathology review of resected tissue. Specificity was determined by testing 275 volunteers who were healthy and with nontransitional cell carcinoma conditions. Results: The 21 sites enrolled 176 patients with a history of transitional cell carcinoma, with 62 recurrences while undergoing surveillance. Overall sensitivities (with 95% CI) were FISH 71% (95% CI 58 to 82), BTA Stat test 50% (37 to 63) and cytology 26% (16 to 39). FISH was negative in 260 of the 275 healthy volunteers or patients with no history of transitional cell carcinoma (specificity 94.5%). Conclusions: Sensitivity of the FISH assay is superior to that of cytology and at least equivalent to the BTA Stat test in detecting recurrent transitional cell carcinoma. Its specificity approaches that of cytology. Further testing of its clinical use is warranted.

Original languageEnglish (US)
Pages (from-to)1950-1954
Number of pages5
JournalJournal of Urology
Volume168
Issue number5
DOIs
StatePublished - Nov 1 2002

Fingerprint

Transitional Cell Carcinoma
Fluorescence In Situ Hybridization
Urinary Bladder Neoplasms
Cell Biology
Healthy Volunteers
Urine
Carcinoma
Recurrence
Chromosomes, Human, Pair 17
Cystoscopy
Chromosomes, Human, Pair 3
Chromosomes, Human, Pair 7
Aneuploidy
Multicenter Studies
Volunteers
Pathology

Keywords

  • Bladder neoplasms
  • In situ hybridization, fluorescence

ASJC Scopus subject areas

  • Urology

Cite this

Sarosdy, M. F., Schellhammer, P., Bokinsky, G., Kahn, P., Chao, R., Yore, L., ... Flom, K. (2002). Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. Journal of Urology, 168(5), 1950-1954. https://doi.org/10.1016/S0022-5347(05)64270-X

Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. / Sarosdy, Michael F.; Schellhammer, Paul; Bokinsky, Gary; Kahn, Paul; Chao, Roberto; Yore, Lawrence; Zadra, Joseph; Burzon, Daniel; Osher, Gerald; Bridge, Julia A.; Anderson, Steven; Johansson, Sonny L.; Lieber, Michael; Soloway, Mark; Flom, Kerry.

In: Journal of Urology, Vol. 168, No. 5, 01.11.2002, p. 1950-1954.

Research output: Contribution to journalArticle

Sarosdy, MF, Schellhammer, P, Bokinsky, G, Kahn, P, Chao, R, Yore, L, Zadra, J, Burzon, D, Osher, G, Bridge, JA, Anderson, S, Johansson, SL, Lieber, M, Soloway, M & Flom, K 2002, 'Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer', Journal of Urology, vol. 168, no. 5, pp. 1950-1954. https://doi.org/10.1016/S0022-5347(05)64270-X
Sarosdy, Michael F. ; Schellhammer, Paul ; Bokinsky, Gary ; Kahn, Paul ; Chao, Roberto ; Yore, Lawrence ; Zadra, Joseph ; Burzon, Daniel ; Osher, Gerald ; Bridge, Julia A. ; Anderson, Steven ; Johansson, Sonny L. ; Lieber, Michael ; Soloway, Mark ; Flom, Kerry. / Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. In: Journal of Urology. 2002 ; Vol. 168, No. 5. pp. 1950-1954.
@article{e308b9ab27c94b7cb36270471aaa41c2,
title = "Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer",
abstract = "Purpose: The UroVysion fluorescence in situ hybridization assay (UroVysion Bladder Cancer Recurrence Kit, Vysis, Inc., Downers Grove, Illinois) is a multi-target assay that detects aneuploidy of chromosomes 3, 7 and 17, and loss of the 9p21 band in exfoliated cells in urine from patients with transitional cell carcinoma. We performed 2 multicenter trials. In 1 trial we compared the sensitivity of the FISH assay to the BTA Stat test (Bion Scientific, Redmond, Washington) and voided cytology in the detection of transitional cell carcinoma. In a separate study of healthy volunteers and patients with other (nontransitional cell carcinoma) conditions we determined the specificity of the FISH assay. Materials and Methods: A total of 176 patients with transitional cell carcinoma in the previous 9 months provided voided urine before cystoscopy. Each specimen was split, preserved and shipped to a central laboratory where all 3 tests were performed. All sites were blinded to results. Sensitivity calculations were based on central pathology review of resected tissue. Specificity was determined by testing 275 volunteers who were healthy and with nontransitional cell carcinoma conditions. Results: The 21 sites enrolled 176 patients with a history of transitional cell carcinoma, with 62 recurrences while undergoing surveillance. Overall sensitivities (with 95{\%} CI) were FISH 71{\%} (95{\%} CI 58 to 82), BTA Stat test 50{\%} (37 to 63) and cytology 26{\%} (16 to 39). FISH was negative in 260 of the 275 healthy volunteers or patients with no history of transitional cell carcinoma (specificity 94.5{\%}). Conclusions: Sensitivity of the FISH assay is superior to that of cytology and at least equivalent to the BTA Stat test in detecting recurrent transitional cell carcinoma. Its specificity approaches that of cytology. Further testing of its clinical use is warranted.",
keywords = "Bladder neoplasms, In situ hybridization, fluorescence",
author = "Sarosdy, {Michael F.} and Paul Schellhammer and Gary Bokinsky and Paul Kahn and Roberto Chao and Lawrence Yore and Joseph Zadra and Daniel Burzon and Gerald Osher and Bridge, {Julia A.} and Steven Anderson and Johansson, {Sonny L.} and Michael Lieber and Mark Soloway and Kerry Flom",
year = "2002",
month = "11",
day = "1",
doi = "10.1016/S0022-5347(05)64270-X",
language = "English (US)",
volume = "168",
pages = "1950--1954",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer

AU - Sarosdy, Michael F.

AU - Schellhammer, Paul

AU - Bokinsky, Gary

AU - Kahn, Paul

AU - Chao, Roberto

AU - Yore, Lawrence

AU - Zadra, Joseph

AU - Burzon, Daniel

AU - Osher, Gerald

AU - Bridge, Julia A.

AU - Anderson, Steven

AU - Johansson, Sonny L.

AU - Lieber, Michael

AU - Soloway, Mark

AU - Flom, Kerry

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Purpose: The UroVysion fluorescence in situ hybridization assay (UroVysion Bladder Cancer Recurrence Kit, Vysis, Inc., Downers Grove, Illinois) is a multi-target assay that detects aneuploidy of chromosomes 3, 7 and 17, and loss of the 9p21 band in exfoliated cells in urine from patients with transitional cell carcinoma. We performed 2 multicenter trials. In 1 trial we compared the sensitivity of the FISH assay to the BTA Stat test (Bion Scientific, Redmond, Washington) and voided cytology in the detection of transitional cell carcinoma. In a separate study of healthy volunteers and patients with other (nontransitional cell carcinoma) conditions we determined the specificity of the FISH assay. Materials and Methods: A total of 176 patients with transitional cell carcinoma in the previous 9 months provided voided urine before cystoscopy. Each specimen was split, preserved and shipped to a central laboratory where all 3 tests were performed. All sites were blinded to results. Sensitivity calculations were based on central pathology review of resected tissue. Specificity was determined by testing 275 volunteers who were healthy and with nontransitional cell carcinoma conditions. Results: The 21 sites enrolled 176 patients with a history of transitional cell carcinoma, with 62 recurrences while undergoing surveillance. Overall sensitivities (with 95% CI) were FISH 71% (95% CI 58 to 82), BTA Stat test 50% (37 to 63) and cytology 26% (16 to 39). FISH was negative in 260 of the 275 healthy volunteers or patients with no history of transitional cell carcinoma (specificity 94.5%). Conclusions: Sensitivity of the FISH assay is superior to that of cytology and at least equivalent to the BTA Stat test in detecting recurrent transitional cell carcinoma. Its specificity approaches that of cytology. Further testing of its clinical use is warranted.

AB - Purpose: The UroVysion fluorescence in situ hybridization assay (UroVysion Bladder Cancer Recurrence Kit, Vysis, Inc., Downers Grove, Illinois) is a multi-target assay that detects aneuploidy of chromosomes 3, 7 and 17, and loss of the 9p21 band in exfoliated cells in urine from patients with transitional cell carcinoma. We performed 2 multicenter trials. In 1 trial we compared the sensitivity of the FISH assay to the BTA Stat test (Bion Scientific, Redmond, Washington) and voided cytology in the detection of transitional cell carcinoma. In a separate study of healthy volunteers and patients with other (nontransitional cell carcinoma) conditions we determined the specificity of the FISH assay. Materials and Methods: A total of 176 patients with transitional cell carcinoma in the previous 9 months provided voided urine before cystoscopy. Each specimen was split, preserved and shipped to a central laboratory where all 3 tests were performed. All sites were blinded to results. Sensitivity calculations were based on central pathology review of resected tissue. Specificity was determined by testing 275 volunteers who were healthy and with nontransitional cell carcinoma conditions. Results: The 21 sites enrolled 176 patients with a history of transitional cell carcinoma, with 62 recurrences while undergoing surveillance. Overall sensitivities (with 95% CI) were FISH 71% (95% CI 58 to 82), BTA Stat test 50% (37 to 63) and cytology 26% (16 to 39). FISH was negative in 260 of the 275 healthy volunteers or patients with no history of transitional cell carcinoma (specificity 94.5%). Conclusions: Sensitivity of the FISH assay is superior to that of cytology and at least equivalent to the BTA Stat test in detecting recurrent transitional cell carcinoma. Its specificity approaches that of cytology. Further testing of its clinical use is warranted.

KW - Bladder neoplasms

KW - In situ hybridization, fluorescence

UR - http://www.scopus.com/inward/record.url?scp=0036837272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036837272&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(05)64270-X

DO - 10.1016/S0022-5347(05)64270-X

M3 - Article

C2 - 12394683

AN - SCOPUS:0036837272

VL - 168

SP - 1950

EP - 1954

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -